Unlock instant, AI-driven research and patent intelligence for your innovation.

Methylene butyrolactone diterpene compound with hypoglycemic activity and preparation method and application thereof

A technology of methylene butyrolactone and compounds, which is applied in the field of medicine, can solve the problems of few research reports on chemical components, and achieve the effect of strong inhibitory activity

Active Publication Date: 2018-09-04
ZHEJIANG PHARMA COLLEGE
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Various pharmacodynamic experiments on whole animals, cells, and molecules at home and abroad have proved that Sanbaicao has significant hypoglycemic activity, and can improve insulin resistance and blood coagulation abnormalities at the same time. There are few reports on ingredients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methylene butyrolactone diterpene compound with hypoglycemic activity and preparation method and application thereof
  • Methylene butyrolactone diterpene compound with hypoglycemic activity and preparation method and application thereof
  • Methylene butyrolactone diterpene compound with hypoglycemic activity and preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] The preparation of embodiment 1 methylene butyrolactone diterpene compound

[0030] (1) Get 8kg of Sanbaicao coarse powder, adopt supercritical CO 2 Extraction, extraction pressure 30MPa, extraction temperature 50°C, extraction time 2h, 95% ethanol as entrainer, the amount of entrainer added is 1 times the amount of medicinal materials, and the extract (about 110g) is obtained after vacuum concentration;

[0031] (2) Take the extract from step (1) and go to silica gel column chromatography (wet column loading, dry loading), and then use petroleum ether-ethyl acetate (volume ratio 50:1~0:100), ethyl acetate - Methanol (volume ratio 50: 1 ~ 0: 100) gradient elution to obtain 10 components (Fr.1 ~ Fr.10), according to thin-layer chromatography detection, take the Fr.4 part through the MCI column to remove the pigment (90 % ethanol elution), ODS medium pressure preparation, methanol-water (1:1 ~ 0:1) gradient elution to obtain Fr.4-1 ~ Fr.4-5, Fr.4-3 by semi-preparative HP...

Embodiment 2

[0035] Example 2 In vitro hypoglycemic test

[0036] 1. α-amylase inhibitory activity

[0037] Add 70 μL of PBS salt buffer solution (pH=6.9), 5 μL of 30 μg / mL α-amylase, and 2 μL of a certain concentration of methylenebutyrolactone diterpene sample to a 96-well plate sieve, and add 20 μL after incubating at 37°C for 10 minutes 10% starch substrate, react at 37°C for 20min, add 3μL I 2 -KI solution to stop the reaction, measure the absorbance value (A value) at 550nm; simultaneously set blank control (buffer solution only), negative control (buffer solution and enzyme solution only) and positive control (acarbose). All the above samples and blank reactions were repeated 3 times, and the average value was taken as the experimental data.

[0038] Inhibition rate (%) = [(A 酶 -A 酶空 )-(A 样 -A 样空 )] / (A 酶 -A 酶空 )×100%

[0039] Experimental results: The inhibitory rates of α-amylase at 6 concentrations of 1 μg / mL, 2 μg / mL, 5 μg / mL, 10 μg / mL, 20 μg / mL and 50 μg / mL of the compo...

Embodiment 3

[0044] The preparation of embodiment 3 capsules

[0045] Take the methylenebutyrolactone diterpene prepared in the above-mentioned Example 1 and add an appropriate amount of starch as a pharmaceutical excipient, mix thoroughly, put into capsules, and make capsules for oral use.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a methylene butyrolactone diterpene compound with hypoglycemic activity. The methylene butyrolactone diterpene compound adopts a molecular formula of C20H28O5, an alpha, beta-unsaturated lactone ring exists at the tail end of the structure, and a carboxyl substituent is contained in the molecular chain. In-vitro hypoglycemic activity studies show that the methylene butyrolactone diterpene compound provided by the invention has very strong activity of inhibiting alpha-amylase, alpha-glucosidase and the like, and IC50 is only about one fifteenth of that of a positive medicine (acarbose). The methylene butyrolactone diterpene compound with the hypoglycemic activity, provided by the invention, has strong in-vitro hypoglycemic activity, and is expected to be developed into a novel hypoglycemic medicine.

Description

technical field [0001] The present invention relates to a compound with hypoglycemic activity, in particular to a novel compound of methylenebutyrolactone diterpenoid with hypoglycemic activity extracted and separated from the traditional Chinese medicine Sanbaicao and its use in the prevention and treatment of diabetes. It belongs to the field of medical technology. Background technique [0002] With the improvement of people's living standards, the prevalence of diabetes has increased sharply. At present, there are more than 360 million diabetics in the world, and it is expected to exceed 600 million by 2030. my country has about 92 million diabetic patients, making it the country with the largest number of diabetics in the world. If the metabolic disorder in diabetic patients is not controlled in time, it can cause various acute and chronic complications throughout the body, and can involve damage to multiple organs and tissues, such as blindness, cardiovascular and cere...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D307/58A61K31/365A61P3/10
CPCA61P3/10C07D307/58Y02P20/54
Inventor 陈宏降
Owner ZHEJIANG PHARMA COLLEGE